TIDMSN.
Smith & Nephew Plc
13 November 2017
Smith & Nephew's NAVIO(TM) Surgical System launches the
first robotics-assisted bi-cruciate retaining total knee
replacement
13 November 2017
Smith & Nephew (NYSE:SNN; LSE:SN), the global medical
technology business, today announces completion of the world's
first robotics-assisted bi-cruciate retaining total knee
replacement procedures.
The NAVIO robotics-assisted surgical system aids in implanting
the JOURNEY(TM) II XR (bi-cruciate retaining total knee system)
which is one of the only total knee designs allowing retention of
the ACL, and is designed to improve patient satisfaction. (1)
With this launch, NAVIO now offers both partial and total knee
options that include the first and only robotics-assisted
bi-cruciate retaining knee procedure, commercially available
today.
Drs. Vivek Neginhal (WV), David Rovinsky(HI), and David Fabi
(CA) recently performed the first cases. "I believe that the NAVIO
is able to provide critical elements of success for the JOURNEY II
XR, such as accuracy of tibia component placement and a streamlined
surgical technique." Dr. Neginhal further commented: "I was amazed
at how fluid the knee motion was on the first postop day. My
patients have expressed great satisfaction so far. I believe that
NAVIO's accuracy and flexibility of use combined with JOURNEY II
XR's retention of the patient's cruciate ligaments and
physiological design will truly increase patients' function and
satisfaction."
The NAVIO is a next generation handheld robotics platform
designed to aid surgeons with implant alignment, ligament balancing
and bone preparation - key factors that can drive implant
survivorship.(2,3) The small footprint of NAVIO allows for set up
and portability. Furthermore, the NAVIO robotics-assisted system
does not require a preoperative image, such as a CT scan. This
allows patients to receive the benefits of robotics-assistance
without the extra steps, costs, and radiation associated with
additional preoperative imaging.(4)
"The JOURNEY II XR bi-cruciate retaining knee has the potential
to deliver the best possible outcome for the surgeon and patient
through the preservation of important anatomical structures such as
the ACL. The NAVIO robotics-assisted surgical system enables
accurate tibial implant placement to deliver a more reproducible
surgical technique. We are proud to be the only company to offer
the unique combination of NAVIO robotics-assistance and the JOURNEY
II XR Knee System," said Mike Donoghue, Senior Vice President of
Global Marketing, Orthopaedics at Smith & Nephew.
References
1. Moro-Oka, Taka-Aki, Marc Muenchinger, Jean Pierre Canciani,
and Scott A. Banks."Comparing in Vivo
Kinematics of Anterior Cruciate-retaining and Posterior
Cruciate-retaining Total Knee Arthroplasty." Knee
Surgery, Sports Traumatology, Arthroscopy 15.1 (200&):
93:99. Web.
2. Sharkey, P., et al. "Why Are Total Knee Arthroplasties
Failing Today?" Clinical Orthopaedics and Related Research.
2002 Nov;404:7-13.
3. Siddique, N., Ahmad, Z. "Revision of Unicondylar to Total
Knee Arthroplasty: A Systematic Review" The Open Orthopaedics
Journal 2012;6; (Suppl 2: M2) 268-275
4. Sg2 Healthcare Intelligence. Technology Guide: Orthopedic
Surgical Robotics. 2014.25. Readmissions Reduction Program (HRRP).
CMS.gov. Page last Modified: 04/18/2016 5:08 PM.
- ends -
Enquiries
Media
+44 (0) 1923
Charles Reynolds 477314
Smith & Nephew
Dave Snyder +1 (978) 749-1440
Smith & Nephew
+44 (0) 20 3727
Simon Conway / Debbie Scott 1000
FTI Consulting
Investors
+44 (0) 20 7960
Ingeborg Øie 2285
Smith & Nephew
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKNDDKBDDODD
(END) Dow Jones Newswires
November 13, 2017 08:00 ET (13:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2024 to May 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From May 2023 to May 2024